Vise Technologies Inc. Invests $566,000 in Neurocrine Biosciences, Inc. $NBIX

Vise Technologies Inc. bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 3,360 shares of the company’s stock, valued at approximately $566,000.

Several other large investors have also added to or reduced their stakes in the business. Geneos Wealth Management Inc. raised its stake in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the last quarter. DJE Kapital AG bought a new position in shares of Neurocrine Biosciences in the fourth quarter valued at approximately $28,000. Basecamp Wealth Advisors LLC boosted its position in shares of Neurocrine Biosciences by 582.9% during the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after buying an additional 204 shares during the last quarter. Cassaday & Co Wealth Management LLC purchased a new position in shares of Neurocrine Biosciences during the first quarter valued at approximately $33,000. Finally, Meeder Asset Management Inc. grew its holdings in Neurocrine Biosciences by 651.6% during the fourth quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock worth $33,000 after buying an additional 202 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Insiders Place Their Bets

In related news, insider Julie Cooke sold 36,937 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $156.22, for a total value of $5,770,298.14. Following the transaction, the insider owned 22,374 shares in the company, valued at approximately $3,495,266.28. This represents a 62.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Darin Lippoldt sold 10,000 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $179.60, for a total value of $1,796,000.00. Following the transaction, the insider directly owned 54,729 shares of the company’s stock, valued at approximately $9,829,328.40. This trade represents a 15.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 127,636 shares of company stock valued at $21,059,908 in the last quarter. 4.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Cantor Fitzgerald raised their price objective on Neurocrine Biosciences from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Citigroup upped their target price on shares of Neurocrine Biosciences from $246.00 to $249.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Stifel Nicolaus increased their target price on shares of Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a report on Friday, July 31st. Wall Street Zen lowered shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Sunday, August 9th. Finally, Truist Financial boosted their price target on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average target price of $200.86.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX opened at $153.04 on Tuesday. The company has a market capitalization of $15.56 billion, a PE ratio of 22.44, a price-to-earnings-growth ratio of 0.71 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 52-week low of $122.14 and a 52-week high of $186.12. The company has a 50-day simple moving average of $167.02 and a 200 day simple moving average of $149.06.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, beating analysts’ consensus estimates of $1.65 by $1.20. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The firm had revenue of $959.00 million for the quarter, compared to analysts’ expectations of $891.16 million. During the same period in the previous year, the company earned $1.65 earnings per share. The company’s quarterly revenue was up 39.5% on a year-over-year basis. As a group, analysts forecast that Neurocrine Biosciences, Inc. will post 7.25 EPS for the current fiscal year.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.